Hepatic Cytoreductive Surgery for Neuroendocrine Cancer

Surgical Oncology Clinics of North America

Volumn 16, Issue 3, 2007, Pages 627-637

  Wright, Byron E ^a   Lee, Chris C ^a   Bilchik, Anton J ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; DOXORUBICIN; INTERFERON; OCTREOTIDE; STREPTOZOCIN;

CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FOLLOW UP; GASTROINTESTINAL TUMOR; HORMONE RELEASE; HUMAN; LIVER METASTASIS; LIVER SURGERY; NEUROENDOCRINE TUMOR; QUALITY OF LIFE; REVIEW; SURGICAL MORTALITY; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 34250871227     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.04.009     Document Type: Review

References (40)

1. Pearse A.G. Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin. Proc R Soc Lond B Biol Sci 170 18 (1968) 71-80
2. Kvols L.K., Perry R.R., Vinik A.I., et al. Neoplasms of the neuroendocrine system and neoplasms of the gastroenteropancreatic endocrine system. In: Kufe D.W., Pollock R.E., Weichselbaum R.R., et al. (Eds). Cancer medicine. 6th edition (2003), B.C. Decker, Houston (TX) 1121-1172
3. Rindi G., Capella C., and Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J Mol Med 76 6 (1998) 413-420
4. Vinik A.I., and Perry R.R. Neoplasms of the gastroenteropancreatic endocrine system. In: Holland J.F., Bast Jr. R.C., and Morton D.L. (Eds). Cancer Medicine 4th edition. vol. 1 (1997), Williams and Wilkins, Baltimore (MD) p. 1605-41
5. Modlin I.M., Lye K.D., and Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 4 (2003) 934-959
6. Williams E.D., and Sandler M. The classification of carcinoid tumors. Lancet 1 (1963) 238-239
7. Service F.J. Hypoglycemic disorders. N Engl J Med 332 17 (1995) 1144-1152
8. Anthony L.B. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol 31 (1999) S216-S218
9. Arnold R., Trautmann M.E., Creutzfeldt W., et al. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38 3 (1996) 430-438
10. Biesma B., Willemse P.H., Mulder N.H., et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer 66 5 (1992) 850-855
11. Fjallskog M.L., Sundin A., Westlin J.E., et al. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 19 1 (2002) 35-42
12. Jacobsen M.B., Hanssen L.E., Kolmannskog F., et al. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol 30 8 (1995) 789-796
13. Moertel C.G., Rubin J., and Kvols L.K. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7 7 (1989) 865-868
14. Wong R.J., and DeCosse J.J. Cytoreductive surgery. Surg Gynecol Obstet 170 3 (1990) 276-281
15. Knox C.D., Feurer I.D., Wise P.E., et al. Survival and functional quality of life after resection for hepatic carcinoid metastasis. J Gastrointest Surg 8 6 (2004) 653-659
16. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169 1 (1995) 36-42
17. McEntee G.P., Nagorney D.M., Kvols L.K., et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 6 (1990) 1091-1096
18. Norton J.A., Doppman J.L., and Jensen R.T. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg 215 1 (1992) 8-18
19. Proye C. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg 25 6 (2001) 685-688
20. Moertel C.G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5 10 (1987) 1502-1522
21. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 3 (1999) 309-318
22. Hughes K.S., Simon R., Songhoradbodi S., et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100 2 (1986) 278-284
23. Kato T., Yasui K., Hirai T., et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of heatetomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46 (2003) S22-S31
24. Scheele J., Stang R., Altendorf-Hofmann A., et al. Resection of colorectal liver metastases. World J Surg 19 1 (1995) 59-71
25. O'Toole D., and Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 19 4 (2005) 585-594
26. Fox D.J., and Khattar R.S. Carcinoid heart disease: presentation, diagnosis, and management. Heart 90 10 (2004) 1224-1228
27. Melendez J.A., Arslan V., Fischer M.E., et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg 187 6 (1998) 620-625
28. McDonald M.L., Nagorney D.M., Connolly H.M., et al. Carcinoid heart disease and carcinoid syndrome; successful surgical treatment. Ann Thorac Surg 67 2 (1999) 537-539
29. Stella M., Decian F., Mithieux F., et al. Ileal carcinoid with liver metastasis presenting after ten years with abdominal mass and right heart failure: report of a case. Tumori 92 1 (2006) 83-85
30. Amersi F.F., Garza A.M., Ahmed A., et al. Survival benefit of extensive hepatic cytoreduction for symptomatic metastases from neuroendocrine tumors. Ann Surg Oncol 13 Suppl 2 (2006) 14
31. Hibi T., Sano T., Sakamoto Y., et al. Surgery for hepatic neuroendocrine tumors: a single institutional experience in Japan. Jpn J Clin Oncol 37 2 (2007) 102-107
32. Musunuru S., Chen H., Rajpal S., et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 141 (2006) 1000-1004
33. Norton J.A., Warren R.S., Kelly M.G., et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134 6 (2003) 1057-1063
34. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197 1 (2003) 29-37
35. Yao K.A., Talamonti M.S., Nemcek A., et al. Indications and results of liver resection and hepatic chemoembolization for metastatic for metastatic gastrointestinal neuroendocrine tumors. Surgery 130 4 (2001) 677-682
36. Jaeck D., Oussoultzoglou E., Bachellier P., et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 25 6 (2001) 689-692
37. Nave H., Mossinger E., Feist H., et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 129 (2001) 170-175
38. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 4 (2000) 432-445
39. Grazi G.L., Cescon M., Pierangeli F., et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 47 32 (2000) 481-486
40. Osborne D.A., Zervos E.E., Strosberg J., et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13 4 (2006) 572-581